- Home
- HEPA
as 11-15-2024 4:00pm EST
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EDISON |
| Market Cap: | 4.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 39.0K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $4.47 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Hepion Pharmaceuticals Inc. News
HEPA Breaking Stock News: Dive into HEPA Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
GlobeNewswire
2 months ago
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
GlobeNewswire
4 months ago
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
The Telegraph
5 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
5 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
AFP
5 months ago
Seoul resumes loudspeaker propaganda against North
Simply Wall St.
5 months ago
Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss
Simply Wall St.
5 months ago
American Software Full Year 2024 Earnings: EPS Beats Expectations
Compare HEPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HEPA Hepion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.